+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Therapeutic Antibody Engineering"

Aß Monoclonal Antibody Drug Market - Global Forecast 2025-2030 - Product Thumbnail Image

Aß Monoclonal Antibody Drug Market - Global Forecast 2025-2030

  • Report
  • August 2025
  • 197 Pages
  • Global
From
Autoimmune Monoclonal Antibody Market Report 2025 - Product Thumbnail Image

Autoimmune Monoclonal Antibody Market Report 2025

  • Report
  • September 2025
  • 250 Pages
  • Global
From
From
From
From
From
From
Loading Indicator

Therapeutic Antibody Engineering is a field of biotechnology that focuses on the development of antibodies for therapeutic use. These antibodies are designed to target specific molecules or cells in the body, and can be used to treat a variety of diseases. The process of engineering therapeutic antibodies involves the use of recombinant DNA technology to create antibodies with desired properties. This technology is used to modify existing antibodies or to create new ones from scratch. The therapeutic antibody engineering market is driven by the increasing demand for treatments for diseases such as cancer, autoimmune diseases, and infectious diseases. The market is also driven by advances in technology, which have enabled the development of more effective and efficient therapeutic antibodies. Some companies in the therapeutic antibody engineering market include AbbVie, Amgen, AstraZeneca, Biogen, Genentech, GlaxoSmithKline, Merck, Novartis, Pfizer, and Regeneron. Show Less Read more